THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA;THE UAB RESEARCH FOUNDATION
发明人:
Eugenia Kharlampieva,Veronika Kozlovskaya,Jason Warram,Mark Bolding,Yuping Bao
申请号：
US16210397
公开号：
US20200179295A1
申请日:
2018.12.05
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The theranostic biocompatible microcapsules provided are efficient contrast enhanced imaging agents that combine Magnetic Resonance Imaging (MRI) with ultrasound-triggered drug release for real-time tracking and targeted delivery in vivo. The capsules are assembled via layer-by-layer deposition of the natural polyphenol tannic acid and poly(N-vinylpyrrolidone) with iron oxide nanoparticles incorporated in the capsule wall. The nanoparticle-modified capsules exhibit enhanced T1 and T2 MRI contrast in a clinical MRI scanner. Loaded with the an anticancer drug such as doxorubicin the capsules circulate in the blood stream for at least 48 hours, an improvement compared to non-encapsulated nanoparticles. High-intensity focused ultrasound results in targeted drug release with a 16-fold increase in the pharmacologically active agent localization in tumors compared to off-target organs. Owing to the active contrast, long circulation, customizable size, shape, composition, and precise delivery of high payload concentrations, these materials present an improved platform for imaging-guided precision drug delivery.
